Develops antibody medicines that target growth factors for people with spinal muscular atrophy and other rare neuromuscular diseases.
10-K for FY2025, filed Mar 3, 2026We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and…View ↗
Apitegromab is a novel, investigational, fully human monoclonal antibody that inhibits myostatin activation by selectively binding the pro-…View ↗
Our clinical-stage pipeline also includes SRK-439, a novel, investigational, subcutaneously administered fully human anti-pro/latent…View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$107.2MView ↗
8-K, filed Sep 14, 2026
On September 11, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug…View ↗
Portfolio focus
The portfolio has shifted from programs spanning neuromuscular disease, cancer, fibrosis and iron-restricted anemia toward a rare-neuromuscular focus; the company is seeking partners for its cancer, fibrosis and anemia programs.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 3, 2026Based on this proprietary and scalable technology platform, we are building a growing portfolio of novel product candidates with the aim of…View ↗
SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (“TGFβ1”), for the treatment of cancers that are…View ↗
Potent and selective inhibitors of the activation of TGFβ for the treatment of fibrotic diseases. We are advancing multiple antibody…View ↗
Additional discovery and early preclinical programs related to the selective modulation of growth factor signaling including bone…View ↗
Competes with Roche, Biogen, NMD Pharma, Novartis, AbbVie, Bicara Therapeutics, Bristol Myers Squibb, and Merck
10-K for FY2025, filed Mar 3, 2026We are developing apitegromab, an investigational fully human monoclonal antibody designed to inhibit myostatin activation by selectively…View ↗
Loading...